Scilex is a biopharmaceutical company that acquires, develops, and commercializes non-opioid pain management products for acute and chronic pain conditions with significant unmet medical needs. The company generates revenue from three FDA-approved commercial products—ZTlido (lidocaine topical system for neuropathic pain), ELYXYB (oral celecoxib solution for migraine), and GLOPERBA (liquid colchicine for gout prophylaxis)—which it promotes through a dedicated sales force to pain specialists, neurologists, primary care physicians, and other healthcare providers. Scilex also maintains a pipeline of product candidates in development, including SP-102 for sciatica pain and SP-103 and SP-104 for other pain indications, leveraging its established commercial infrastructure and payor relationships to drive growth across its portfolio.